New Discoveries in Migraine Mechanisms and Therapeutic Targets

Overview

Journal Curr Opin Physiol

Date 2019 Dec 10

PMID 31815209

Citations 9

Authors

Greg Dussor

Affiliations

Soon will be listed here.

Abstract

Migraine is among the most common and most disabling disorders worldwide, yet its underlying pathophysiology is among the most poorly understood. New information continues to emerge on mechanisms within the central and peripheral nervous systems that may contribute to migraine attacks. Additionally, new therapeutics have recently become available and along with much needed relief for many patients, these drugs provide insight into the disorder based on their mechanism of action. This review will cover new findings within the last several years that add to the understanding of migraine pathophysiology, including those related to the vasculature, calcitonin gene-related peptide (CGRP), and mechanisms within the cortex and meninges that may contribute to attacks. Discussion will also cover recent findings on novel therapeutic targets, several of which continue to show promise in new preclinical studies, including acid-sensing ion channels (ASICs) and the delta-opioid receptor (DOR).

Citing Articles

The mechanism and potential therapeutic target of piezo channels in pain.

Xu Y, Wang Y, Mei S, Hu J, Wu L, Xu L Front Pain Res (Lausanne). 2024; 5:1452389.

PMID: 39398533 PMC: 11466900. DOI: 10.3389/fpain.2024.1452389.

Migraine and Its Treatment from the Medicinal Chemistry Perspective.

Pehlivanlar E, Carradori S, Simsek R ACS Pharmacol Transl Sci. 2024; 7(4):951-966.

PMID: 38633587 PMC: 11020076. DOI: 10.1021/acsptsci.3c00370.

CGRP-targeted medication in chronic migraine - systematic review.

Oliveira R, Gil-Gouveia R, Puledda F J Headache Pain. 2024; 25(1):51.

PMID: 38575868 PMC: 10996229. DOI: 10.1186/s10194-024-01753-y.

TMEM100, a regulator of TRPV1-TRPA1 interaction, contributes to temporomandibular disorder pain.

Wang P, Zhang Q, Dias F, Suttle A, Dong X, Chen Y Front Mol Neurosci. 2023; 16:1160206.

PMID: 37033371 PMC: 10077888. DOI: 10.3389/fnmol.2023.1160206.

CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.

Russo A, Hay D Physiol Rev. 2022; 103(2):1565-1644.

PMID: 36454715 PMC: 9988538. DOI: 10.1152/physrev.00059.2021.

References

Zhao J, Levy D . Dissociation between CSD-Evoked Metabolic Perturbations and Meningeal Afferent Activation and Sensitization: Implications for Mechanisms of Migraine Headache Onset. J Neurosci. 2018; 38(22):5053-5066. PMC: 6705945. DOI: 10.1523/JNEUROSCI.0115-18.2018. View

Meylakh N, Marciszewski K, Di Pietro F, Macefield V, Macey P, Henderson L . Deep in the brain: Changes in subcortical function immediately preceding a migraine attack. Hum Brain Mapp. 2018; 39(6):2651-2663. PMC: 6866635. DOI: 10.1002/hbm.24030. View

Gormley P, Anttila V, Winsvold B, Palta P, Esko T, Pers T . Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016; 48(8):856-66. PMC: 5331903. DOI: 10.1038/ng.3598. View

Filiz A, Tepe N, Eftekhari S, Boran H, Dilekoz E, Edvinsson L . CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia. 2017; 39(3):354-365. DOI: 10.1177/0333102417735845. View

Hougaard A, Amin F, Christensen C, Younis S, Wolfram F, Cramer S . Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 2017; 140(6):1633-1642. DOI: 10.1093/brain/awx089. View

Mason B, Kaiser E, Kuburas A, Loomis M, Latham J, Garcia-Martinez L . Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms. J Neurosci. 2017; 37(1):204-216. PMC: 5214631. DOI: 10.1523/JNEUROSCI.2967-16.2016. View

Zhao J, Levy D . Cortical Spreading Depression Promotes Persistent Mechanical Sensitization of Intracranial Meningeal Afferents: Implications for the Intracranial Mechanosensitivity of Migraine. eNeuro. 2017; 3(6). PMC: 5242377. DOI: 10.1523/ENEURO.0287-16.2016. View

Bernstein C, Nir R, Noseda R, Fulton A, Huntington S, Lee A . The migraine eye: distinct rod-driven retinal pathways' response to dim light challenges the visual cortex hyperexcitability theory. Pain. 2018; 160(3):569-578. PMC: 6460478. DOI: 10.1097/j.pain.0000000000001434. View

Zhao J, Levy D . The CGRP receptor antagonist BIBN4096 inhibits prolonged meningeal afferent activation evoked by brief local K stimulation but not cortical spreading depression-induced afferent sensitization. Pain Rep. 2018; 3(1):e632. PMC: 5802320. DOI: 10.1097/PR9.0000000000000632. View

10.

Ghanizada H, Al-Karagholi M, Arngrim N, Ghanizada M, Larsson H, Amin F . Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study. Peptides. 2019; 121:170134. DOI: 10.1016/j.peptides.2019.170134. View

11.

Avona A, Burgos-Vega C, Burton M, Akopian A, Price T, Dussor G . Dural Calcitonin Gene-Related Peptide Produces Female-Specific Responses in Rodent Migraine Models. J Neurosci. 2019; 39(22):4323-4331. PMC: 6538861. DOI: 10.1523/JNEUROSCI.0364-19.2019. View

12.

Cottier K, Galloway E, Calabrese E, Tome M, Liktor-Busa E, Kim J . Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery. eNeuro. 2018; 5(4). PMC: 6071204. DOI: 10.1523/ENEURO.0116-18.2018. View

13.

Noseda R, Melo-Carrillo A, Nir R, Strassman A, Burstein R . Non-Trigeminal Nociceptive Innervation of the Posterior Dura: Implications to Occipital Headache. J Neurosci. 2019; 39(10):1867-1880. PMC: 6407291. DOI: 10.1523/JNEUROSCI.2153-18.2018. View

14.

Wang S, Wu B, Liu C, Qin G, Yan W, Zhou J . Expression of ASIC3 in the Trigeminal Nucleus Caudalis Plays a Role in a Rat Model of Recurrent Migraine. J Mol Neurosci. 2018; 66(1):44-52. DOI: 10.1007/s12031-018-1113-3. View

15.

Haulund Vollesen A, Amin F, Ashina M . Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. Neurotherapeutics. 2018; 15(2):371-376. PMC: 5935633. DOI: 10.1007/s13311-017-0596-x. View

16.

Leimuranta P, Khiroug L, Giniatullin R . Emerging Role of (Endo)Cannabinoids in Migraine. Front Pharmacol. 2018; 9:420. PMC: 5928495. DOI: 10.3389/fphar.2018.00420. View

17.

Kilic K, Karatas H, Donmez-Demir B, Eren-Kocak E, Gursoy-Ozdemir Y, Can A . Inadequate brain glycogen or sleep increases spreading depression susceptibility. Ann Neurol. 2017; 83(1):61-73. DOI: 10.1002/ana.25122. View

18.

Burstein R, Noseda R, Borsook D . Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015; 35(17):6619-29. PMC: 4412887. DOI: 10.1523/JNEUROSCI.0373-15.2015. View

19.

Jacobs B, Dussor G . Neurovascular contributions to migraine: Moving beyond vasodilation. Neuroscience. 2016; 338:130-144. PMC: 5083225. DOI: 10.1016/j.neuroscience.2016.06.012. View

20.

Gupta R, Hadaya J, Trehan A, Zekavat S, Roselli C, Klarin D . A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression. Cell. 2017; 170(3):522-533.e15. PMC: 5785707. DOI: 10.1016/j.cell.2017.06.049. View